Yungjin Pharm. Co., Ltd.

KSE 003520.KS

Yungjin Pharm. Co., Ltd. Gross Profit for the year ending December 31, 2023: USD 55.39 M

Yungjin Pharm. Co., Ltd. Gross Profit is USD 55.39 M for the year ending December 31, 2023, a 8.31% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Yungjin Pharm. Co., Ltd. Gross Profit for the year ending December 31, 2022 was USD 51.14 M, a 5.46% change year over year.
Yungjin Pharm. Co., Ltd. Gross Profit for the year ending December 31, 2021 was USD 48.49 M, a -28.09% change year over year.
Yungjin Pharm. Co., Ltd. Gross Profit for the year ending December 31, 2020 was USD 67.44 M, a -1.93% change year over year.
Yungjin Pharm. Co., Ltd. Gross Profit for the year ending December 31, 2019 was USD 68.76 M, a 25.19% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

KSE: 003520.KS

Yungjin Pharm. Co., Ltd.

CEO	Mr. Chae-Joon Lee
IPO Date	Jan. 8, 2001
Location	South Korea
Headquarters	13, Olympic-ro 35da-gil
Employees	574
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea. It provides cephalosporin antibiotic, antipsychotic, cardiovascular, and nutrition products. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. is a subsidiary of KT&G Corporation.

Key trends

Past 5 years